Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Preskorn, SH' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 76 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Harvey, AT; Preskorn, SH
      Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    2. Shad, MU; Marsh, C; Preskorn, SH
      The economic consequences of a drug-drug interaction

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    3. Fava, M; Dunner, DL; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J; Cohen, M
      Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial

      JOURNAL OF CLINICAL PSYCHIATRY
    4. Khan, AY; Preskorn, SH
      Increase in plasma levels of clozapine and norclozapine after administration of nefazodone

      JOURNAL OF CLINICAL PSYCHIATRY
    5. Findling, RL; Preskorn, SH; Marcus, RN; Magnus, RD; D'Amico, F; Marathe, P; Reed, MD
      Nefazodone pharmacokinetics in depressed children and adolescents

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    6. Preskorn, SH; Greenblatt, DJ; Harvey, AT
      Lack of effect of sertraline on the pharmacokinetics of alprazolam

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    7. Shad, MU; Preskorn, SH; Izgur, Z
      Failure to consider drug-drug interactions as a likely cause of behavioraldeterioration in a patient with bipolar disorder

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    8. Khan, A; Shad, MU; Preskorn, SH
      Lack of sertraline efficacy probably due to an interaction with carbamazepine

      JOURNAL OF CLINICAL PSYCHIATRY
    9. Harvey, AT; Rudolph, RL; Preskorn, SH
      Evidence of the dual mechanisms of action of venlafaxine

      ARCHIVES OF GENERAL PSYCHIATRY
    10. Burke, MJ; Preskorn, SH
      Therapeutic drug monitoring of antidepressants - Cost implications and relevance to clinical practice

      CLINICAL PHARMACOKINETICS
    11. Shad, MU; Preskorn, SH
      Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as aresult of fluoxetine discontinuation

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    12. Preskorn, SH
      The selection of the antidepressant in clinical practice

      DEPRESSIVE DISORDERS, VOL 1
    13. Preskorn, SH
      Treatment of depression in the "old-old"

      DEPRESSIVE DISORDERS, VOL 1
    14. BHATARA VS; MAGNUS RD; PAUL KL; PRESKORN SH
      SEROTONIN SYNDROME INDUCED BY VENLAFAXINE AND FLUOXETINE - A CASE-STUDY IN POLYPHARMACY AND POTENTIAL PHARMACODYNAMIC AND PHARMACOKINETIC MECHANISMS

      The Annals of pharmacotherapy
    15. HORST WD; PRESKORN SH
      THE PHARMACOLOGY AND MODE OF ACTION OF VENLAFAXINE

      Reviews in contemporary pharmacotherapy
    16. UDDIN M; PRESKORN SH
      PHARMACODYNAMIC AND PHARMACOKINETIC FACTORS IN A CASE OF NEUROLEPTIC MALIGNANT SYNDROME

      Journal of clinical psychopharmacology
    17. PRESKORN SH
      DEBATE RESOLVED - THERE ARE DIFFERENTIAL-EFFECTS OF SEROTONIN SELECTIVE REUPTAKE INHIBITORS ON CYTOCHROME-P450 ENZYMES

      JOURNAL OF PSYCHOPHARMACOLOGY
    18. Horst, WD; Preskorn, SH
      Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

      JOURNAL OF AFFECTIVE DISORDERS
    19. PRESKORN SH
      CLINICALLY RELEVANT PHARMACOLOGY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS - AN OVERVIEW WITH EMPHASIS ON PHARMACOKINETICS AND EFFECTS ON OXIDATIVE DRUG-METABOLISM

      Clinical pharmacokinetics
    20. PRESKORN SH
      FOREWORD

      Clinical pharmacokinetics
    21. TREMAINE LM; WILNER KD; PRESKORN SH
      A STUDY OF THE POTENTIAL EFFECT OF SERTRALINE ON THE PHARMACOKINETICSAND PROTEIN-BINDING OF TOLBUTAMIDE

      Clinical pharmacokinetics
    22. GARDNER MJ; BARIS BA; WILNER KD; PRESKORN SH
      EFFECT OF SERTRALINE ON THE PHARMACOKINETICS AND PROTEIN-BINDING OF DIAZEPAM IN HEALTHY-VOLUNTEERS

      Clinical pharmacokinetics
    23. ALDERMAN J; PRESKORN SH; GREENBLATT DJ; HARRISON W; PENENBERG D; ALLISON J; CHUNG M
      DESIPRAMINE PHARMACOKINETICS WHEN COADMINISTERED WITH PAROXETINE OR SERTRALINE IN EXTENSIVE METABOLIZERS

      Journal of clinical psychopharmacology
    24. SHAD MU; PRESKORN SH
      A POSSIBLE BUPROPION AND IMIPRAMINE INTERACTION

      Journal of clinical psychopharmacology
    25. CATTERSON ML; PRESKORN SH; MARTIN RL
      PHARMACODYNAMIC AND PHARMACOKINETIC CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY

      The Psychiatric clinics of North America
    26. PRESKORN SH
      SELECTION OF AN ANTIDEPRESSANT - MIRTAZAPINE

      The Journal of clinical psychiatry
    27. PRESKORN SH; BAKER B
      FATALITY ASSOCIATED WITH COMBINED FLUOXETINE-AMITRIPTYLINE THERAPY

      JAMA, the journal of the American Medical Association
    28. PRESKORN SH; ALDERMAN J; GREENBLATT DJ; HORST WD
      SERTRALINE DOES NOT INHIBIT CYTOCHROME-P450 3A-MEDIATED DRUG-METABOLISM IN-VIVO

      Psychopharmacology bulletin
    29. MAGNUS RD; FINDLING R; PRESKORN SH; FRIESEN S; MARCUS R; MARATHE P; DAMICO F
      AN OPEN-LABEL PHARMACOKINETIC TRIAL OF NEFAZODONE IN DEPRESSED CHILDREN AND ADOLESCENTS

      Psychopharmacology bulletin
    30. PRESKORN SH; HORST WD; ALDERMAN J; GREENBLATT DJ
      SERTRALINE DOES NOT INHIBIT CYTOCHROME (CYP) 3A-MEDIATED DRUG-METABOLISM

      Psychopharmacology bulletin
    31. HARVEY AT; PRESKORN SH
      MECHANISM OF ACTION OF VENLAFAXINE IN NORMAL-MALE VOLUNTEERS

      Clinical pharmacology and therapeutics
    32. PRESKORN SH; OMO K; MAGNUS R; SHAD M
      IMMEDIATE CROSSOVER FROM FLUOXETINE TO MIRTAZAPINE

      Biological psychiatry
    33. PRESKORN SH
      TANDOSPIRONE

      CNS DRUGS
    34. CATTERSON ML; PRESKORN SH
      PHARMACOKINETICS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS - CLINICAL RELEVANCE

      Pharmacology & toxicology
    35. HARVEY AT; PRESKORN SH
      CYTOCHROME-P450 ENZYMES - INTERPRETATION OF THEIR INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS .2.

      Journal of clinical psychopharmacology
    36. HARVEY AT; PRESKORN SH
      CYTOCHROME-P450 ENZYMES - INTERPRETATION OF THEIR INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS .1.

      Journal of clinical psychopharmacology
    37. PRESKORN SH
      DRUG-DRUG INTERACTIONS

      The Journal of clinical psychiatry
    38. PRESKORN SH
      REDUCING THE RISK OF DRUG-DRUG INTERACTIONS - A GOAL OF RATIONAL DRUGDEVELOPMENT

      The Journal of clinical psychiatry
    39. BURKE MJ; CARMICHAEL C; HARVEY A; PRESKORN SH
      THE PREVALENCE OF POLYPHARMACY AS A POTENTIAL RISK FOR DRUG-INTERACTIONS IN THE OUTPATIENT TREATMENT OF MAJOR DEPRESSION AND THE INPATIENT TREATMENT OF SCHIZOPHRENIA

      Psychopharmacology bulletin
    40. PRESKORN SH; HARVEY AT
      BIOCHEMICAL AND CLINICAL DOSE-RESPONSE CURVES WITH SERTRALINE

      Clinical pharmacology and therapeutics
    41. PRESKORN SH
      EFFECTS OF ANTIDEPRESSANTS ON THE CYTOCHROME-P450 SYSTEM

      The American journal of psychiatry
    42. BURKE MJ; HARVEY AT; PRESKORN SH
      PHARMACOKINETICS OF THE NEWER ANTIDEPRESSANTS

      The American journal of medicine
    43. PRESKORN SH
      SHOULD RATIONAL DRUG DEVELOPMENT IN PSYCHIATRY TARGET MORE THAN ONE MECHANISM OF ACTION IN A SINGLE-MOLECULE

      International review of psychiatry
    44. PRESKORN SH; LANE RM
      SERTRALINE 50 MG DAILY - THE OPTIMAL DOSE IN THE TREATMENT OF DEPRESSION

      International clinical psychopharmacology
    45. PRESKORN SH
      COMPARISON OF THE TOLERABILITY OF BUPROPION, FLUOXETINE, IMIPRAMINE, NEFAZODONE, PAROXETINE, SERTRALINE, AND VENLAFAXINE

      The Journal of clinical psychiatry
    46. PRESKORN SH
      BEYOND DSM-IV - WHAT IS THE CART AND WHAT IS THE HORSE

      Psychiatric annals
    47. PRESKORN SH; BAKER BS
      OUTPATIENT MANAGEMENT OF THE DEPRESSED PATIENT

      Disease-a-month
    48. HARVEY AT; PRESKORN SH
      INTERACTIONS OF SEROTONIN REUPTAKE INHIBITORS WITH TRICYCLIC ANTIDEPRESSANTS

      Archives of general psychiatry
    49. LACEY RL; PRESKORN SH; JERKOVICH GS
      IS RISPERIDONE A SUBSTITUTE FOR CLOZAPINE FOR PATIENTS WHO DO NOT RESPOND TO NEUROLEPTICS

      The American journal of psychiatry
    50. PRESKORN SH
      THERAPEUTIC DRUG-MONITORING WITH TRICYCLIC ANTIDEPRESSANTS - A RESPONSE

      Journal of clinical psychopharmacology
    51. PRESKORN SH; ALDERMAN J; CHUNG M; HARRISON W; MESSIG M; HARRIS S
      PHARMACOKINETICS OF DESIPRAMINE COADMINISTERED WITH SERTRALINE OR FLUOXETINE

      Journal of clinical psychopharmacology
    52. WELLER RA; KAPADIA P; WELLER EB; FRISTAD M; LAZAROFF LB; PRESKORN SH
      PSYCHOPATHOLOGY IN FAMILIES OF CHILDREN WITH MAJOR DEPRESSIVE-DISORDERS

      Journal of affective disorders
    53. PRESKORN SH
      PRESKORN REPLIES

      The Journal of clinical psychiatry
    54. PRESKORN SH
      UPDATE ON ANTIDEPRESSANT THERAPY - INTRODUCTION

      The Journal of clinical psychiatry
    55. PRESKORN SH
      ANTIDEPRESSANT DRUG SELECTION - CRITERIA AND OPTIONS

      The Journal of clinical psychiatry
    56. RICHELSON E; PRESKORN SH; FEIGHNER JP; CUNNINGHAM LA; ROOSE SP; KELLER MB
      ANTIDEPRESSANT DRUG SELECTION - CRITERIA AND OPTIONS - DISCUSSION

      The Journal of clinical psychiatry
    57. FEIGHNER JP; KELLER MB; PRESKORN SH; ROOSE SP; DREVETS WC
      THE NATURAL-HISTORY AND HETEROGENEITY OF DEPRESSIVE-DISORDERS - IMPLICATIONS FOR RATIONAL ANTIDEPRESSANT THERAPY - DISCUSSION

      The Journal of clinical psychiatry
    58. PRESKORN SH; RICHELSON E; ROOSE SP; FEIGHNER JP; CUNNINGHAM LA; DREVETS WC
      THE PHARMACOLOGY OF ANTIDEPRESSANTS AT THE SYNAPSE - FOCUS ON NEWER COMPOUNDS - DISCUSSION

      The Journal of clinical psychiatry
    59. BURKE MJ; SILKEY B; PRESKORN SH
      PHARMACOECONOMIC CONSIDERATIONS WHEN EVALUATING TREATMENT OPTIONS FORMAJOR DEPRESSIVE DISORDER

      The Journal of clinical psychiatry
    60. FEIGHNER JP; BURKE MJ; PRESKORN SH; KELLER MB; DREVETS WC
      PHARMACOECONOMIC CONSIDERATIONS WHEN EVALUATING TREATMENT OPTIONS FORMAJOR DEPRESSION - DISCUSSION

      The Journal of clinical psychiatry
    61. ROOSE SP; NIERENBERG AA; PRESKORN SH; FEIGHNER JP; DREVETS WC
      THE TREATMENT OF SEVERE DEPRESSION - IS THERE AN EFFICACY GAP BETWEENSSRI AND TCA ANTIDEPRESSANT GENERATIONS - DISCUSSION

      The Journal of clinical psychiatry
    62. CUNNINGHAM LA; FEIGHNER JP; ROOSE SP; RICHELSON E; PRESKORN SH; DREVETS WC
      THE ROLE OF VENLAFAXINE IN RATIONAL ANTIDEPRESSANT THERAPY - DISCUSSION

      The Journal of clinical psychiatry
    63. RICHELSON E; DREVETS WC; PRESKORN SH
      GERIATRIC DEPRESSION - BRAIN IMAGING CORRELATES AND PHARMACOLOGICAL CONSIDERATIONS - DISCUSSION

      The Journal of clinical psychiatry
    64. FEIGHNER JP; ROOSE SP; PRESKORN SH
      ANTIDEPRESSANT CHOICE IN THE PATIENT WITH CARDIAC DISEASE - LESSONS FROM THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL (CAST) STUDIES - DISCUSSION

      The Journal of clinical psychiatry
    65. PRESKORN SH; CUNNINGHAM LA; ROOSE SP
      DEPRESSION IN THE MEDICALLY ILL - CHOOSING AN ANTIDEPRESSANT - DISCUSSION

      The Journal of clinical psychiatry
    66. PRESKORN SH; FEIGHNER JP; CUNNINGHAM LA; ROOSE SP; BURKE MJ
      FACTORS TO CONSIDER IN SELECTING AN ANTIDEPRESSANT - CONCLUDING DISCUSSION

      The Journal of clinical psychiatry
    67. PRESKORN SH; MAGNUS RD
      INHIBITION OF HEPATIC P-450 ISOENZYMES BY SEROTONIN SELECTIVE REUPTAKE INHIBITORS - IN-VITRO AND IN-VIVO FINDINGS AND THEIR IMPLICATIONS FOR PATIENT-CARE

      Psychopharmacology bulletin
    68. PRESKORN SH; MAGNUS RD
      INHIBITION OF HEPATIC P-450 ISOENZYMES BY SEROTONIN SELECTIVE REUPTAKE INHIBITORS - IN-VITRO AND IN-VIVO FINDINGS AND THEIR IMPLICATIONS FOR PATIENT-CARE

      Psychopharmacology bulletin
    69. HUGHES CW; PRESKORN SH
      PHARMACOKINETICS IN CHILD ADOLESCENT PSYCHIATRIC-DISORDERS/

      Psychiatric annals
    70. PRESKORN SH; BURKE MJ; FAST GA
      THERAPEUTIC DRUG-MONITORING - PRINCIPLES AND PRACTICE

      The Psychiatric clinics of North America
    71. PRESKORN SH
      PHARMACOKINETICS OF PSYCHOTROPIC AGENTS - WHY AND HOW THEY ARE RELEVANT TO TREATMENT - INTRODUCTION

      The Journal of clinical psychiatry
    72. PRESKORN SH
      PHARMACOKINETICS OF ANTIDEPRESSANTS - WHY AND HOW THEY ARE RELEVANT TO TREATMENT

      The Journal of clinical psychiatry
    73. PRESKORN SH
      MONITORING ANTIDEPRESSANT-INDUCED CEREBRAL HYPEREXCITABILITY - REPLY

      The Journal of clinical psychiatry
    74. MARTIN RL; PRESKORN SH
      SPECIAL AND INNOVATIVE USES OF BENZODIAZEPINES - INTRODUCTION AND RAISON-DETRE

      Psychiatric annals
    75. HORST WD; PRESKORN SH
      THE ROLE OF BENZODIAZEPINES IN THE TREATMENT OF PSYCHOTIC DISORDERS

      Psychiatric annals
    76. PRESKORN SH
      RECENT PHARMACOLOGICAL ADVANCES IN ANTIDEPRESSANT THERAPY FOR THE ELDERLY

      The American journal of medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/21 alle ore 08:13:07